BIOSECURE Act of 2025

Sponsor: Gary C. Peters (Democratic-MI)December 11, 2025

AI-generated ?

Report an error

Introduced

In Committee

Passed One Chamber

Passed Both Chambers

Signed into Law

Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Blocks federal agencies from using biotech from companies that pose a national security risk.

This bill would stop federal agencies from buying biotech equipment or services from certain companies deemed a national security risk. It would also prevent agencies from giving out federal loans or grants that would be used with these companies. This aims to protect sensitive U.S. data and supply chains.

What Would Change

Today, federal agencies and those receiving federal funds can use biotechnology products and services from a wide range of companies without specific legal prohibitions based on national security risks. After this bill, federal agencies would be blocked from buying or using biotechnology from companies identified as "biotechnology companies of concern," and from contracting with other companies that use these risky products. Federal loan and grant money would also be restricted from these uses, aiming to protect national security and sensitive data.

Key Provisions

Blocks federal agencies from buying or using biotechnology equipment or services from "biotechnology companies of concern."
Prevents federal agencies from signing contracts with companies that use risky biotechnology products in their work for the government.
Stops federal loan or grant money from being used to buy or use risky biotechnology products, or to contract with companies that do.
Requires the Office of Management and Budget to create and regularly update a list of "biotechnology companies of concern" within one year.
Exempts U.S. intelligence activities and overseas healthcare for U.S. personnel from these prohibitions.
Allows federal agencies to waive these prohibitions in specific cases, such as for overseas healthcare, with approval and notification to Congress.

View on Congress.gov

S 3469 · 119th Congress · December 11, 2025 · AI Summary by gemini-2.5-flash · 10/10

Requires the Director of National Intelligence (DNI) to assess national security risks from foreign adversaries collecting U.S. citizen multiomic data and report findings to Congress within 30 days of completing the assessment (due within 270 days of the bill becoming law).

Requires the DNI to submit an annual report to Congress on intelligence about harmful activities by biotechnology companies involving human multiomic data, starting 180 days after the bill becomes law.

Allows drug manufacturers to be considered compliant with certain federal drug price rules if they would meet the rules but are prevented by this bill's prohibitions.

Lobbying Activity

2 filings mentioned this bill

Top Lobbying Clients

ASSOCIATION FOR ACCESSIBLE MEDICINES

2 filings

Top Lobbying Firms

1.ASSOCIATION FOR ACCESSIBLE MEDICINES2 filings

Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.

Take Action on This Bill

Write a Letter

Send a letter to your representatives via ResistBot

Text 50409 Open ResistBot